摘要
目的探讨黄葵胶囊联合复方α酮酸片治疗慢性肾衰竭的疗效及对Scr、BUN水平影响。方法选取医院收治的慢性肾衰竭患者67例,随机分为对照组34例和试验组33例。对照组患者给予复方α酮酸片,试验组在对照组基础上给予黄葵胶囊,两组患者均持续治疗1个月,后续治疗门诊随访。对比两组患者的临床疗效、中医证候评分、β2-MG、Cys-C和CRP水平、BUN、SCr、SF-36评分、血清TP、Alb和Hb水平及不良反应情况。结果治疗后,试验组总有效率较高(P<0.05);两组患者治疗前中医证候评分比较差异无统计学意义(P>0.05);两组患者治疗后腰膝酸软、倦怠乏力、夜尿清长、食少纳呆等证候评分显著降低(P<0.05);并且试验组降低较明显(P<0.05);两组治疗前血清β2-MG、Cys-C和CRP水平比较差异无统计学意义(P>0.05);两组治疗后血清β2-MG、Cys-C和CRP水平显著降低(P<0.05);并且试验组降低较明显(P<0.05);两组治疗前BUN、SCr比较差异无统计学意义(P>0.05);两组患者治疗后BUN、SCr明显降低(P<0.05);并且治疗组降低较多(P<0.05);两组患者治疗前血清TP、Alb和Hb水平比较差异无统计学意义(P>0.05);两组患者治疗后血清TP、Alb和Hb水平明显升高(P<0.05);且治疗组升高较多(P<0.05);两组患者治疗后SF-36评分显著升高(P<0.05);并且治疗组升高较多(P<0.05);两组高钙血症、恶心、呕吐等不良反应发生率明比较差异无统计学意义(P>0.05)。结论采用黄葵胶囊联合复方α酮酸片治疗慢性肾衰竭具有较好的治疗效果,值得在临床上推广应用。
Objective To investigate the effect of Huangkui Capsule(黄葵胶囊) combined with Compound α-Ketoacid Tablets in the treatment of chronic renal failure and its effect on the levels of Scr and BUN. Methods Sixty-seven patients with chronic renal failure admitted to our hospital were randomly divided into the control group(34 cases) and the experimental group(33 cases). Patients in the control group were given Compound α-Ketoacid Tablets, and those in the experimental group were given Huangkui Capsule on the basis of the control group. Patients in both groups were treated continuously for 1 month, followed up by outpatient follow-up. The clinical efficacy, TCM syndrome score, levels of β2-MG, CYS-C,CRP, BUN and SCr, SF-36 score, serum levels of TP, Alb and Hb and adverse reactions were compared between the two groups. Results After treatment, the total effective rate of the experimental group was higher(P<0.05). There was no difference in scores of TCM syndromes before treatment between the two groups(P>0.05). The scores of symptoms such as weak waist and knee, tiredness and fatigue, long night-urine clear and poor appetite in two groups were significantly reduced(P<0.05). In the experimental group, the decrease was more significant(P<0.05). There was no difference in serum levels of β2-MG, CYS-C and CRP between the two groups before treatment(P>0.05). After treatment, serum levels of β2-MG, CYS-C and CRP in the two groups were significantly decreased(P<0.05). In the experimental group, the decrease was more significant(P<0.05). There was no difference in BUN or SCr before treatment between the two groups(P>0.05). After treatment, BUN and SCr were significantly decreased in both groups(P<0.05). In addition, there was a significant decrease in the treatment group(P<0.05). There was no difference in serum levels of TP, Alb or Hb between the two groups before treatment(P>0.05). The serum levels of TP, Alb and Hb of the two groups were significantly increased after treatment(P<0.05). The increase in the treatment group was significant(P<0.05). After treatment, the SF-36 score in both groups was significantly increased(P<0.05). In addition, there were significant increases in the treatment group(P<0.05). The incidence of adverse reactions such as hypercalcemia, nausea and vomiting was not significantly different between the two groups P>0.05). Conclusion Huangkui Capsule combined with Compound α-Ketoacid Tablets has a good therapeutic effect in the treatment of chronic renal failure, worthy of clinical application.
作者
蒋宏伟
杜浩昌
杜渊
JIANG Hongwei;DU Haochang;DU Yuan(Department of Nephrology,Jiangnan University Hospital,Wuxi 214062,Jiangsu,China)
出处
《中华中医药学刊》
CAS
北大核心
2021年第9期244-248,共5页
Chinese Archives of Traditional Chinese Medicine
基金
江苏省“六大人才高峰”D类基金项目(2015-WSN-089)。
关键词
黄葵胶囊
复方α酮酸片
慢性肾衰竭
临床疗效
SCR
BUN
Huangkui Capsule(黄葵胶囊)
Compoundα-Ketoacid Tablets
chronic kidney failure
clinical efficacy
Scr
BUN